KK
Therapeutic Areas
Assembly Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ABI-5366 | Recurrent Genital Herpes (HSV-2) | Phase 1b |
| ABI-1179 | Recurrent Genital Herpes (HSV-2) | Phase 1b |
| ABI-6250 | Chronic Hepatitis D (HDV) | Phase 1 |
| ABI-4334 | Chronic Hepatitis B (HBV) | Phase 1 |
| NNPI Program | Transplant-Associated Herpesviruses | Research |
| IFNAR Agonist Program | Hepatitis B & D | Research |
Leadership Team at Assembly Biosciences
JO
Jason Okazaki
Chief Executive Officer & President, Director
WD
William Delaney, PhD
Chief Scientific Officer
AG
Anuj Gaggar, MD, PhD
Chief Medical Officer
JT
Jennifer Troia
Chief Human Resources Officer
NS
Nicole S. White, PhD
Chief Manufacturing Officer
WR
William Ringo
Chairman of the Board, Non-Executive
SM
Sir Michael Houghton, PhD
Director